Watch Live

Tweet TWEET

Updates on Ongoing Clinical Trials and Retail Expansions - Research Report on Achillion, Medivation, ACADIA, Halozyme, and

Updates on Ongoing Clinical Trials and Retail Expansions - Research Report on
   Achillion, Medivation, ACADIA, Halozyme, and Charles River Laboratories

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 5, 2013

NEW YORK, July 5, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Medivation, Inc. (NASDAQ:
MDVN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics, Inc.
(NASDAQ: HALO), and Charles River Laboratories International, Inc. (NYSE:
CRL). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Achillion Pharmaceuticals, Inc. Research Report

On July 1, 2013, Achillion Pharmaceuticals, Inc. (Achillion) announced that
the Company has received a notice from the US Food and Drug Administration
(FDA) that placed sovaprevir on clinical hold after elevations in liver
enzymes associated with significantly higher than anticipated exposures to
atazanivir and sovaprevir were noted in a Phase 1 healthy subject drug-drug
interaction (DDI) study, which evaluated the effects of concomitant
administration of sovaprevir with ritonavir-boosted atazanavir. In order to
resolve the clinical hold, the FDA has asked Achillion to submit study reports
from two DDI studies and an integrated safety analysis of ongoing sovaprevir
trials, which the latter expects to provide in approximately six weeks.
Further, Achillion announced that the FDA has allowed the Company to continue
with the enrollment and treatment of patients in the Phase 2-007 clinical
trial, which evaluates 12-weeks of sovaprevir in combination with ACH-3102 and
ribavirin for patients with treatment-naive genotype 1 hepatitis C viral
infection (HCV). The Full Research Report on Achillion Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0fa0_ACHN]

--

Medivation, Inc. Research Report

On June 26, 2013, Medivation, Inc. (Medivation) and Astellas Pharma Inc.
(Astellas) jointly announced the enrollment of their first patient in a global
Phase 2 clinical trial to evaluate enzalutamide as a single agent for the
treatment of advanced, androgen receptor (AR)-positive, triple-negative breast
cancer (TNBC). The Companies intend to enroll approximately 80 patients with
AR-positive, TNBC at different sites in the US, Canada and Europe, under its
Phase 2 open label trial. "The initiation of this Phase 2 study marks an
important milestone as we expand our enzalutamide development program beyond
prostate cancer to explore the clinical efficacy of enzalutamide in
triple-negative breast cancer, where there is a significant unmet medical
need," said David Hung, M.D., President and CEO of Medivation. Hung further
added that the partnership intends to present the results from the Phase 1
study at an upcoming scientific conference. The Full Research Report on
Medivation, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/4e75_MDVN]

--

ACADIA Pharmaceuticals Inc. Research Report

On July 1, 2013, ACADIA Pharmaceuticals Inc. (ACADIA) announced that the
Company has been added to the Russell 2000 Index, with effect from June 28,
2013 after the market closes. ACADIA has also managed to find a place in the
Russell 3000 and Russell Global Indexes, which are widely used by investment
managers and institutional investors for index funds and as benchmarks for
passive and active investment strategies. In a release made by the Company on
July 2, 2013, ACADIA is set to present at the 8^th Annual JMP Securities
Healthcare Conference on July 9, 2013, 1:00 p.m. Eastern Time at The St. Regis
New York. The Full Research Report on ACADIA Pharmaceuticals Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/34b6_ACAD]

--

Halozyme Therapeutics, Inc. Research Report

On June 30, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced interim
results from a proof of concept Phase 1/2 clinical trial, which was conducted
to evaluate the activity and local tolerability of HTI-501 for use in
aesthetic dermatology. In the Phase 1/2 study, 83% of the subjects showed
improvement from the pretreatment assessment, with a median improvement of 53%
(p=.006) by the primary physician assessment. "In the initial patients treated
thus far, the response to treatment with HTI-501 has been encouraging," said
Francisco Perez, M.D., immediate past President of World Congress of Cosmetic
Dermatology and Principal Clinical Investigator. "We are particularly
interested in subsequent three and six month observations, which have shown
further improvement in some subjects treated thus far." The Full Research
Report on Halozyme Therapeutics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/eb1a_HALO]

--

Charles River Laboratories International, Inc. Research Report

On July 2, 2013, Charles River Laboratories International, Inc. (Charles River
Laboratories) reported that the Company will release its Q2 2013 financial
results on July 31, 2013, after the market closes. A conference call has been
scheduled on August 1, 2013, at 9:00 a.m. Eastern Time, to discuss the
financial results. At its Q1 2013 earnings release, James C. Foster, Chairman
and CEO of Charles River Laboratories, stated, "While demand for research
models was slower than expected at the beginning of the year, we believe that
trends will improve as we progress through 2013. As a result, we continue to
expect to achieve our 2013 guidance of 4% to 6% constant-currency sales
growth, and non-GAAP earnings per share in a range between $2.80 and $2.90."
The Full Research Report on Charles River Laboratories International, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/a979_CRL]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)